Zai Lab (ZLAB) Scheduled to Post Quarterly Earnings on Tuesday

Zai Lab (NASDAQ:ZLAB) is scheduled to be releasing its earnings data before the market opens on Tuesday, November 12th. Analysts expect Zai Lab to post earnings of ($0.71) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Zai Lab Trading Down 0.6 %

Shares of NASDAQ ZLAB opened at $30.62 on Friday. The company has a market capitalization of $3.05 billion, a P/E ratio of -10.01 and a beta of 1.04. Zai Lab has a 12 month low of $13.48 and a 12 month high of $36.60. The stock has a 50 day moving average of $25.16 and a 200-day moving average of $20.65.

Insider Buying and Selling at Zai Lab

In other news, insider Joshua L. Smiley sold 4,352 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $16.67, for a total transaction of $72,547.84. Following the transaction, the insider now directly owns 43,232 shares of the company’s stock, valued at approximately $720,677.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 13.88% of the company’s stock.

Wall Street Analyst Weigh In

ZLAB has been the topic of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a research note on Friday, October 25th. JPMorgan Chase & Co. increased their target price on Zai Lab from $38.00 to $44.00 and gave the stock an “overweight” rating in a research note on Monday, October 21st.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.